WC
AIMT

Wexford Capital’s Aimmune Therapeutics AIMT Stock Holding History

Wexford Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-23,000
Closed -$770K – 178
2019
Q4 		$770K Sell
23,000
-7,000
-23% -$196K 0.12% 89
2019
Q3 		$628K Sell
30,000
-7,580
-20% -$155K 0.09% 89
2019
Q2 		$782K Hold
37,580
– – 0.09% 95
2019
Q1 		$840K Buy
+37,580
New +$885K 0.07% 72

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wexford Capital's AIMT Position: Q1 2020 in Review

Wexford Capital sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 23,000 shares — an estimated $770K sold.

Wexford Capital first reported a position in AIMT in Q1 2019 and held it in 4 quarters. The position peaked at $840K in Q1 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Wexford Capital reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Wexford Capital sold 23,000 Aimmune Therapeutics shares in Q1 2020, an estimated $770K.
  • Wexford Capital first reported a position in Aimmune Therapeutics in Q1 2019 and held it in 4 quarters.
  • Wexford Capital's Aimmune Therapeutics position peaked at $840K in Q1 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Wexford Capital's 13F filing for Q1 2020, filed 18 May 2020.